Tien Dong1, Andrew Aronsohn2, K Gautham Reddy2, Helen S Te2. 1. Department of Medicine, UCLA Hospitals, 10945 Le Conte Ave, PVUB 2114 MC694907, Los Angeles, CA, 90095, USA. tsdong@mednet.ucla.edu. 2. Department of Medicine, Center for Liver Diseases, University of Chicago Medicine, Chicago, IL, USA.
Abstract
BACKGROUND: While the effects of rifaximin have been shown to be protective against acute kidney injury (AKI) and hepatorenal syndrome (HRS) in alcohol-induced cirrhosis, its long-term effects on the renal function of other cirrhotic patients are unknown. AIM: To examine the long-term effects of rifaximin on the renal function of patients with cirrhosis from various etiologies. METHODS: In a retrospective study, we examined cirrhotic patients at the University of Chicago Liver Clinic from January 1, 2011, to December 31, 2014. The study enrolled patients on rifaximin for ≥90 days, who were then matched by age, gender, and MELD score to a control group. Patients with malignancy and renal replacement therapy (RRT) at baseline were excluded. Data were censored at the last follow-up, termination of rifaximin therapy, initiation of RRT, death, or liver transplant. RESULTS: Eighty-eight rifaximin cases were identified and matched to 88 control cases. Baseline characteristics were similar, with the exceptions of more prevalent long-term midodrine use (≥90 days) (17.0 vs 4.5 %, p = 0.01) and baseline ascites (37.5 vs 23.8 %, p = 0.05) in the rifaximin group. There was no difference in the frequency of infections, deaths, liver transplants, or hospitalizations. After controlling for cofounders, the incidence rate ratio of AKI (IRR 0.71, p = 0.02) and HRS (IRR 0.21, p = 0.02), as well as the risk of requiring RRT (OR 0.23, p = 0.01), was lower in the rifaximin group. CONCLUSIONS: Long-term use of rifaximin is associated with a decrease incidence of AKI and HRS and a decrease risk of requiring RRT in a general population of cirrhotic patients.
BACKGROUND: While the effects of rifaximin have been shown to be protective against acute kidney injury (AKI) and hepatorenal syndrome (HRS) in alcohol-induced cirrhosis, its long-term effects on the renal function of other cirrhotic patients are unknown. AIM: To examine the long-term effects of rifaximin on the renal function of patients with cirrhosis from various etiologies. METHODS: In a retrospective study, we examined cirrhotic patients at the University of Chicago Liver Clinic from January 1, 2011, to December 31, 2014. The study enrolled patients on rifaximin for ≥90 days, who were then matched by age, gender, and MELD score to a control group. Patients with malignancy and renal replacement therapy (RRT) at baseline were excluded. Data were censored at the last follow-up, termination of rifaximin therapy, initiation of RRT, death, or liver transplant. RESULTS: Eighty-eight rifaximin cases were identified and matched to 88 control cases. Baseline characteristics were similar, with the exceptions of more prevalent long-term midodrine use (≥90 days) (17.0 vs 4.5 %, p = 0.01) and baseline ascites (37.5 vs 23.8 %, p = 0.05) in the rifaximin group. There was no difference in the frequency of infections, deaths, liver transplants, or hospitalizations. After controlling for cofounders, the incidence rate ratio of AKI (IRR 0.71, p = 0.02) and HRS (IRR 0.21, p = 0.02), as well as the risk of requiring RRT (OR 0.23, p = 0.01), was lower in the rifaximin group. CONCLUSIONS: Long-term use of rifaximin is associated with a decrease incidence of AKI and HRS and a decrease risk of requiring RRT in a general population of cirrhotic patients.
Authors: Oliver Witzke; Markus Baumann; Daniel Patschan; Susann Patschan; Anna Mitchell; Ulrich Treichel; Guido Gerken; Thomas Philipp; Andreas Kribben Journal: J Gastroenterol Hepatol Date: 2004-12 Impact factor: 4.029
Authors: M Navasa; A Follo; X Filella; W Jiménez; A Francitorra; R Planas; A Rimola; V Arroyo; J Rodés Journal: Hepatology Date: 1998-05 Impact factor: 17.425
Authors: Paolo Angeli; Pere Ginès; Florence Wong; Mauro Bernardi; Thomas D Boyer; Alexander Gerbes; Richard Moreau; Rajiv Jalan; Shiv K Sarin; Salvatore Piano; Kevin Moore; Samuel S Lee; Francois Durand; Francesco Salerno; Paolo Caraceni; W Ray Kim; Vicente Arroyo; Guadalupe Garcia-Tsao Journal: J Hepatol Date: 2015-01-28 Impact factor: 25.083
Authors: Justin M Belcher; Guadalupe Garcia-Tsao; Arun J Sanyal; Harjit Bhogal; Joseph K Lim; Naheed Ansari; Steven G Coca; Chirag R Parikh Journal: Hepatology Date: 2012-12-06 Impact factor: 17.425
Authors: Kevin D Mullen; Arun J Sanyal; Nathan M Bass; Fred F Poordad; Muhammad Y Sheikh; R Todd Frederick; Enoch Bortey; William P Forbes Journal: Clin Gastroenterol Hepatol Date: 2013-12-21 Impact factor: 11.382
Authors: R S Lin; F Y Lee; S D Lee; Y T Tsai; H C Lin; R H Lu; W C Hsu; C C Huang; S S Wang; K J Lo Journal: J Hepatol Date: 1995-02 Impact factor: 25.083
Authors: Lawrence Mj Best; Suzanne C Freeman; Alex J Sutton; Nicola J Cooper; Eng-Loon Tng; Mario Csenar; Neil Hawkins; Chavdar S Pavlov; Brian R Davidson; Douglas Thorburn; Maxine Cowlin; Elisabeth Jane Milne; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy Journal: Cochrane Database Syst Rev Date: 2019-09-12